title: [Guideline 'Diagnosis and treatment of oesophageal carcinoma'].
abstract: An evidence-based guideline for the diagnosis and treatment of oesophageal carcinoma was developed on the initiative of the Netherlands Society of Gastroenterohepatology in cooperation with the Dutch Institute for Healthcare Improvement (CBO) and the Dutch Association of Comprehensive Cancer Centres. If a patient with oesophageal carcinoma is eligible for treatment with curative intent, they should undergo thoracic and abdominal CT, ultrasound investigation of the supraclavicular region and endoscopic ultrasonography for staging purposes. Endoscopic therapy is the preferred treatment for high-grade dysplasia or early cancer in Barrett's oesophagus confined to the mucosa. Surgical resection is indicated if the tumour invades the submucosa. If resection of the oesophageal carcinoma is performed with curative intent, one should aim for radical resection. The type and extent of the resection depends on the location of the tumour. There is evidence that the mortality rate following surgery can be reduced by performing it in centres with ample experience with oesophageal cancer surgery. Preoperative chemotherapy and radiotherapy may improve survival in patients with oesophageal carcinoma. Palliative treatment for oesophageal carcinoma should be considered in cases of local invasion of surrounding organs, metastases, poor physical condition of the patient or recurrent disease after previous curative treatment. Psychosocial support is an important element in the follow-up of patients with oesophageal carcinoma.
authors.affiliation: Erasmus MC-Centrum, Rotterdam. p.siersema@erasmusmc.nl
authors.forename: P D
authors.initials: PD
authors.lastname: Siersema
authors.forename: C J G M
authors.initials: CJ
authors.lastname: Rosenbrand
authors.forename: J J G H M
authors.initials: JJ
authors.lastname: Bergman
authors.forename: A
authors.initials: A
authors.lastname: van der Gaast
authors.forename: C
authors.initials: C
authors.lastname: Goedhart
authors.forename: D J
authors.initials: DJ
authors.lastname: Richel
authors.forename: L P S
authors.initials: LP
authors.lastname: Stassen
authors.forename: H W
authors.initials: HW
authors.lastname: Tilanus
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D019317:Evidence-Based Medicine; D006801:Humans; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents